Opioids Market by Product Type (Codeine, Fentanyl, Oxycodone, Methadone, Morphine, Hydrocodone, and Others) and Application (Pain Management, Cough Treatment, and Diarrhea Treatment): Global Opportunity Analysis and Industry Forecast, 2021-2030
The global opioids market was valued at $4,412.48 million in 2020, and is projected to reach $6,060.17 million by 2030, registering a CAGR of 3.2% from 2021 to 2030.
Opioids are pain relievers because they include substances that relax muscles and alleviate pain and stress. Prescription opioids are primarily used to treat moderate to severe pain, while some opioids can be used to alleviate coughing and diarrhea. Hydrocodone, oxycodone, codeine, fentanyl, methadone, morphine, and other pharmaceutical opioids are among them. Opioids are the most commonly prescribed pain relievers for people suffering from moderate to severe chronic pain. These analgesics are used to treat severe continuous pain in individuals with terminal conditions and to manage pain in cancer patients.
The growth of the global opioids market is driven by alarming increase in incidence of orthopedic diseases & chronic pain. Furthermore, rise in disposable income and surge in geriatric population are expected to propel the growth of the global opioids market. However, emergence and legalization of cannabis as an alternative to opioids impede the growth of the market. On the contrary, increase in consumption of opioids analgesic for pain management in developing countries is anticipated to create lucrative opportunities for market expansion in the near future.
The opioids market is segmented on the basis of type of product, application, and region. According to type of product, the market is classified into codeine, fentanyl, oxycodone, methadone, morphine, hydrocodone, and others. On the basis of application, the market is divided into pain management, cough treatment, and diarrhea treatment. The pain management segment is further divided into neuropathic pain, migraine, back pain, osteoarthritis pain, and cancer pain. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include Purdue Pharma LP, AstraZeneca Plc., C.H. Boehringer Sohn Ag and Ko. Kg, Johnson and Johnson Inc., Sanofi S.A, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals Inc., Pfizer, Inc., Sun Pharmaceuticals, and Teva Pharmaceuticals.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global opioids market and current & future trends to elucidate the imminent investment pockets.
Information about key drivers, restrains, and opportunities and their impact analysis on the market size is provided.
Porter’s five forces analysis illustrates the potency of buyers and suppliers operating in the industry.
The quantitative analysis of the global market from 2021 to 2030 is provided to determine the market potential.
By Product
Codeine
Fentanyl
Oxycodone
Methadone
Morphine
Hydrocodone
Others.
By Applications
Pain management
Cough treatment
Diarrhea treatment
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
KEY Players
AstraZeneca PLC
Purdue Pharma LP
Johnson and Johnson Inc.
Sanofi S.A
Mallinckrodt Pharmaceuticals
Endo Pharmaceuticals Inc.
Pfizer, Inc.
Sun Pharmaceuticals
Teva Pharmaceuticals
C.H. Boehringer Sohn Ag and ko. Kg
- CHAPTER 1:INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1.Primary Research
- 1.4.2.Secondary Research
- 1.4.3.Analyst Tools and Models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3:MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1.Top Investment Pockets
- 3.2.2.Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1.Bargaining Power of Suppliers
- 3.3.2.Threat of New Entrants
- 3.3.3.Threat of Substitutes
- 3.3.4.Competitive Rivalry
- 3.3.5.Bargaining Power among Buyers
- 3.4. Market Share Analysis/Top Player Positioning
- 3.4.1.Market Share Analysis/Top Player Positioning 2020
- 3.5. Market Dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis
- CHAPTER 4:OPIOIDS MARKET, BY PRODUCT TYPE
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Product Type
- 4.2.Fentanyl
- 4.2.1.Key Market Trends, Growth Factors and Opportunities
- 4.2.2.Market Size and Forecast, By Region
- 4.2.3.Market Share Analysis, By Country
- 4.3.Oxycodone
- 4.3.1.Key Market Trends, Growth Factors and Opportunities
- 4.3.2.Market Size and Forecast, By Region
- 4.3.3.Market Share Analysis, By Country
- 4.4.Methadone
- 4.4.1.Key Market Trends, Growth Factors and Opportunities
- 4.4.2.Market Size and Forecast, By Region
- 4.4.3.Market Share Analysis, By Country
- 4.5.Morphine
- 4.5.1.Key Market Trends, Growth Factors and Opportunities
- 4.5.2.Market Size and Forecast, By Region
- 4.5.3.Market Share Analysis, By Country
- 4.6.Hydrocodone
- 4.6.1.Key Market Trends, Growth Factors and Opportunities
- 4.6.2.Market Size and Forecast, By Region
- 4.6.3.Market Share Analysis, By Country
- 4.7.Others
- 4.7.1.Key Market Trends, Growth Factors and Opportunities
- 4.7.2.Market Size and Forecast, By Region
- 4.7.3.Market Share Analysis, By Country
- CHAPTER 5:OPIOIDS MARKET, BY APPLICATION
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Application
- 5.2.Pain Management
- 5.2.1.Key Market Trends, Growth Factors and Opportunities
- 5.2.2.Market Size and Forecast, By Region
- 5.2.3.Market Share Analysis, By Country
- 5.3.Cough Treatment
- 5.3.1.Key Market Trends, Growth Factors and Opportunities
- 5.3.2.Market Size and Forecast, By Region
- 5.3.3.Market Share Analysis, By Country
- 5.4.Diarrhea Treatment
- 5.4.1.Key Market Trends, Growth Factors and Opportunities
- 5.4.2.Market Size and Forecast, By Region
- 5.4.3.Market Share Analysis, By Country
- CHAPTER 6:OPIOIDS MARKET, BY REGION
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Region
- 6.2. North America
- 6.2.1.Key Market Trends and Opportunities
- 6.2.2.Market Size and Forecast, By Product Type
- 6.2.3.Market Size and Forecast, By Application
- 6.2.4.Market Size and Forecast, By Country
- 6.2.5.U.s. Opioids Market
- 6.2.5.1.Market Size and Forecast, By Product Type
- 6.2.5.2.Market Size and Forecast, By Application
- 6.2.6.Canada Opioids Market
- 6.2.6.1.Market Size and Forecast, By Product Type
- 6.2.6.2.Market Size and Forecast, By Application
- 6.2.7.Mexico Opioids Market
- 6.2.7.1.Market Size and Forecast, By Product Type
- 6.2.7.2.Market Size and Forecast, By Application
- 6.3. Europe
- 6.3.1.Key Market Trends and Opportunities
- 6.3.2.Market Size and Forecast, By Product Type
- 6.3.3.Market Size and Forecast, By Application
- 6.3.4.Market Size and Forecast, By Country
- 6.3.5.Germany Opioids Market
- 6.3.5.1.Market Size and Forecast, By Product Type
- 6.3.5.2.Market Size and Forecast, By Application
- 6.3.6.France Opioids Market
- 6.3.6.1.Market Size and Forecast, By Product Type
- 6.3.6.2.Market Size and Forecast, By Application
- 6.3.7.Uk Opioids Market
- 6.3.7.1.Market Size and Forecast, By Product Type
- 6.3.7.2.Market Size and Forecast, By Application
- 6.3.8.Italy Opioids Market
- 6.3.8.1.Market Size and Forecast, By Product Type
- 6.3.8.2.Market Size and Forecast, By Application
- 6.3.9.Spain Opioids Market
- 6.3.9.1.Market Size and Forecast, By Product Type
- 6.3.9.2.Market Size and Forecast, By Application
- 6.3.10.Rest Of Europe Opioids Market
- 6.3.10.1.Market Size and Forecast, By Product Type
- 6.3.10.2.Market Size and Forecast, By Application
- 6.4. Asia-Pacific
- 6.4.1.Key Market Trends and Opportunities
- 6.4.2.Market Size and Forecast, By Product Type
- 6.4.3.Market Size and Forecast, By Application
- 6.4.4.Market Size and Forecast, By Country
- 6.4.5.Japan Opioids Market
- 6.4.5.1.Market Size and Forecast, By Product Type
- 6.4.5.2.Market Size and Forecast, By Application
- 6.4.6.China Opioids Market
- 6.4.6.1.Market Size and Forecast, By Product Type
- 6.4.6.2.Market Size and Forecast, By Application
- 6.4.7.Australia Opioids Market
- 6.4.7.1.Market Size and Forecast, By Product Type
- 6.4.7.2.Market Size and Forecast, By Application
- 6.4.8.India Opioids Market
- 6.4.8.1.Market Size and Forecast, By Product Type
- 6.4.8.2.Market Size and Forecast, By Application
- 6.4.9.South Korea Opioids Market
- 6.4.9.1.Market Size and Forecast, By Product Type
- 6.4.9.2.Market Size and Forecast, By Application
- 6.4.10.Rest of Asia Pacific Opioids Market
- 6.4.10.1.Market Size and Forecast, By Product Type
- 6.4.10.2.Market Size and Forecast, By Application
- 6.5. LAMEA
- 6.5.1.Key Market Trends and Opportunities
- 6.5.2.Market Size and Forecast, By Product Type
- 6.5.3.Market Size and Forecast, By Application
- 6.5.4.Market Size and Forecast, By Country
- 6.5.5.Brazil Opioids Market
- 6.5.5.1.Market Size and Forecast, By Product Type
- 6.5.5.2.Market Size and Forecast, By Application
- 6.5.6.Saudi Arabia Opioids Market
- 6.5.6.1.Market Size and Forecast, By Product Type
- 6.5.6.2.Market Size and Forecast, By Application
- 6.5.7.South Africa Opioids Market
- 6.5.7.1.Market Size and Forecast, By Product Type
- 6.5.7.2.Market Size and Forecast, By Application
- 6.5.8.Rest of LAMEA Opioids Market
- 6.5.8.1.Market Size and Forecast, By Product Type
- 6.5.8.2.Market Size and Forecast, By Application
- CHAPTER 7:COMPANY PROFILES
- 7.1.BOEHRINGER INGELHEIM GROUP
- 7.1.1. Company Overview
- 7.1.2. Key Executives
- 7.1.3. Company snapshot
- 7.1.4. Operating business segments
- 7.1.5. Product portfolio
- 7.1.6. Business Performance
- 7.1.7. Key Strategic Moves and Developments
- 7.2.AstraZeneca Plc
- 7.2.1. Company Overview
- 7.2.2. Key Executives
- 7.2.3. Company snapshot
- 7.2.4. Operating business segments
- 7.2.5. Product portfolio
- 7.2.6. Business Performance
- 7.2.7. Key Strategic Moves and Developments
- 7.3.Endo Pharmaceuticals, Inc
- 7.3.1. Company Overview
- 7.3.2. Key Executives
- 7.3.3. Company snapshot
- 7.3.4. Operating business segments
- 7.3.5. Product portfolio
- 7.3.6. Business Performance
- 7.3.7. Key Strategic Moves and Developments
- 7.4.Johnson And Johnson
- 7.4.1. Company Overview
- 7.4.2. Key Executives
- 7.4.3. Company snapshot
- 7.4.4. Operating business segments
- 7.4.5. Product portfolio
- 7.4.6. Business Performance
- 7.4.7. Key Strategic Moves and Developments
- 7.5.MALLINCKRODT PLC
- 7.5.1. Company Overview
- 7.5.2. Key Executives
- 7.5.3. Company snapshot
- 7.5.4. Operating business segments
- 7.5.5. Product portfolio
- 7.5.6. Business Performance
- 7.5.7. Key Strategic Moves and Developments
- 7.6.PFIZER INC
- 7.6.1. Company Overview
- 7.6.2. Key Executives
- 7.6.3. Company snapshot
- 7.6.4. Operating business segments
- 7.6.5. Product portfolio
- 7.6.6. Business Performance
- 7.6.7. Key Strategic Moves and Developments
- 7.7.PURDUE PHARMA L.P
- 7.7.1. Company Overview
- 7.7.2. Key Executives
- 7.7.3. Company snapshot
- 7.7.4. Operating business segments
- 7.7.5. Product portfolio
- 7.7.6. Business Performance
- 7.7.7. Key Strategic Moves and Developments
- 7.8.SANOFI
- 7.8.1. Company Overview
- 7.8.2. Key Executives
- 7.8.3. Company snapshot
- 7.8.4. Operating business segments
- 7.8.5. Product portfolio
- 7.8.6. Business Performance
- 7.8.7. Key Strategic Moves and Developments
- 7.9.Sun Pharmaceutical Industries Ltd
- 7.9.1. Company Overview
- 7.9.2. Key Executives
- 7.9.3. Company snapshot
- 7.9.4. Operating business segments
- 7.9.5. Product portfolio
- 7.9.6. Business Performance
- 7.9.7. Key Strategic Moves and Developments
- 7.10.Teva Pharmaceutical Industries Limited
- 7.10.1. Company Overview
- 7.10.2. Key Executives
- 7.10.3. Company snapshot
- 7.10.4. Operating business segments
- 7.10.5. Product portfolio
- 7.10.6. Business Performance
- 7.10.7. Key Strategic Moves and Developments
- LIST OF TABLES
- TABLE 1.GLOBAL OPIOIDS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 2.GLOBAL OPIOIDS MARKET FOR FENTANYL, BY REGION, 2020-2030 ($MILLION)
- TABLE 3.GLOBAL OPIOIDS MARKET FOR OXYCODONE, BY REGION, 2020-2030 ($MILLION)
- TABLE 4.GLOBAL OPIOIDS MARKET FOR METHADONE, BY REGION, 2020-2030 ($MILLION)
- TABLE 5.GLOBAL OPIOIDS MARKET FOR MORPHINE, BY REGION, 2020-2030 ($MILLION)
- TABLE 6.GLOBAL OPIOIDS MARKET FOR HYDROCODONE, BY REGION, 2020-2030 ($MILLION)
- TABLE 7.GLOBAL OPIOIDS MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
- TABLE 8.GLOBAL OPIOIDS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 9.GLOBAL OPIOIDS MARKET FOR PAIN MANAGEMENT, BY REGION, 2020-2030 ($MILLION)
- TABLE 10.GLOBAL OPIOIDS MARKET FOR COUGH TREATMENT, BY REGION, 2020-2030 ($MILLION)
- TABLE 11.GLOBAL OPIOIDS MARKET FOR DIARRHEA TREATMENT, BY REGION, 2020-2030 ($MILLION)
- TABLE 12.GLOBAL OPIOIDS MARKET, BY REGION, 2020-2030 ($MILLION)
- TABLE 13.NORTH AMERICA OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 14.NORTH AMERICA OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 15.U.S. OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 16.U.S. OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 17.CANADA OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 18.CANADA OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 19.MEXICO OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 20.MEXICO OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 21.EUROPE OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 22.EUROPE OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 23.GERMANY OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 24.GERMANY OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 25.FRANCE OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 26.FRANCE OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 27.UK OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 28.UK OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 29.ITALY OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 30.ITALY OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 31.SPAIN OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 32.SPAIN OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 33.REST OF EUROPE OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 34.REST OF EUROPE OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 35.ASIA-PACIFIC OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 36.ASIA-PACIFIC OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 37.JAPAN OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 38.JAPAN OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 39.CHINA OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 40.CHINA OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 41.AUSTRALIA OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 42.AUSTRALIA OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 43.INDIA OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 44.INDIA OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 45.SOUTH KOREA OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 46.SOUTH KOREA OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 47.REST OF ASIA PACIFIC OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 48.REST OF ASIA PACIFIC OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 49.LAMEA OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 50.LAMEA OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 51.BRAZIL OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 52.BRAZIL OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 53.SAUDI ARABIA OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 54.SAUDI ARABIA OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 55.SOUTH AFRICA OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 56.SOUTH AFRICA OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 57.REST OF LAMEA OPIOIDS, BY PRODUCT TYPE, 2020-2030 ($MILLION)
- TABLE 58.REST OF LAMEA OPIOIDS, BY APPLICATION, 2020-2030 ($MILLION)
- TABLE 59.BOEHRINGER INGELHEIM GROUP: KEY EXECUTIVES
- TABLE 60.BOEHRINGER INGELHEIM GROUP: COMPANY SNAPSHOT
- TABLE 61.BOEHRINGER INGELHEIM GROUP: OPERATING SEGMENTS
- TABLE 62.BOEHRINGER INGELHEIM GROUP: PRODUCT PORTFOLIO
- TABLE 63.BOEHRINGER INGELHEIM GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 64.ASTRAZENECA PLC: KEY EXECUTIVES
- TABLE 65.ASTRAZENECA PLC: COMPANY SNAPSHOT
- TABLE 66.ASTRAZENECA PLC: OPERATING SEGMENTS
- TABLE 67.ASTRAZENECA PLC: PRODUCT PORTFOLIO
- TABLE 68.ASTRAZENECA PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 69.ENDO PHARMACEUTICALS, INC: KEY EXECUTIVES
- TABLE 70.ENDO PHARMACEUTICALS, INC: COMPANY SNAPSHOT
- TABLE 71.ENDO PHARMACEUTICALS, INC: OPERATING SEGMENTS
- TABLE 72.ENDO PHARMACEUTICALS, INC: PRODUCT PORTFOLIO
- TABLE 73.ENDO PHARMACEUTICALS, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 74.JOHNSON AND JOHNSON: KEY EXECUTIVES
- TABLE 75.JOHNSON AND JOHNSON: COMPANY SNAPSHOT
- TABLE 76.JOHNSON AND JOHNSON: OPERATING SEGMENTS
- TABLE 77.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
- TABLE 78.JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 79.MALLINCKRODT PLC: KEY EXECUTIVES
- TABLE 80.MALLINCKRODT PLC: COMPANY SNAPSHOT
- TABLE 81.MALLINCKRODT PLC: OPERATING SEGMENTS
- TABLE 82.MALLINCKRODT PLC: PRODUCT PORTFOLIO
- TABLE 83.MALLINCKRODT PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 84.PFIZER INC: KEY EXECUTIVES
- TABLE 85.PFIZER INC: COMPANY SNAPSHOT
- TABLE 86.PFIZER INC: OPERATING SEGMENTS
- TABLE 87.PFIZER INC: PRODUCT PORTFOLIO
- TABLE 88.PFIZER INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 89.PURDUE PHARMA L.P: KEY EXECUTIVES
- TABLE 90.PURDUE PHARMA L.P: COMPANY SNAPSHOT
- TABLE 91.PURDUE PHARMA L.P: OPERATING SEGMENTS
- TABLE 92.PURDUE PHARMA L.P: PRODUCT PORTFOLIO
- TABLE 93.PURDUE PHARMA L.P: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 94.SANOFI: KEY EXECUTIVES
- TABLE 95.SANOFI: COMPANY SNAPSHOT
- TABLE 96.SANOFI: OPERATING SEGMENTS
- TABLE 97.SANOFI: PRODUCT PORTFOLIO
- TABLE 98.SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 99.SUN PHARMACEUTICAL INDUSTRIES LTD: KEY EXECUTIVES
- TABLE 100.SUN PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
- TABLE 101.SUN PHARMACEUTICAL INDUSTRIES LTD: OPERATING SEGMENTS
- TABLE 102.SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
- TABLE 103.SUN PHARMACEUTICAL INDUSTRIES LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 104.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
- TABLE 105.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
- TABLE 106.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS
- TABLE 107.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
- TABLE 108.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
- LIST OF FIGURES
- FIGURE 1.GLOBAL OPIOIDS MARKET SEGMENTATION
- FIGURE 2.GLOBAL OPIOIDS MARKET
- FIGURE 3.SEGMENTATION OPIOIDS MARKET
- FIGURE 4.TOP INVESTMENT POCKET IN OPIOIDS MARKET
- FIGURE 5.TOP WINNING STRATEGIES, 2019-2021*
- FIGURE 6.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%)
- FIGURE 7.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*
- FIGURE 8.MODERATE BARGAINING POWER OF BUYERS
- FIGURE 9.MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
- FIGURE 11.LOW THREAT OF SUBSTITUTION
- FIGURE 12.HIGH COMPETITIVE RIVALRY
- FIGURE 13.TOP PLAYER POSITIONING, 2020
- FIGURE 14.MARKET SHARE ANALYSIS, 2020
- FIGURE 15.RESTRAINTS AND DRIVERS: OPIOIDS MARKET
- FIGURE 16.OPIOIDS MARKET SEGMENTATION, BY PRODUCT TYPE
- FIGURE 17.OPIOIDS MARKET FOR FENTANYL, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 18.OPIOIDS MARKET FOR OXYCODONE, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 19.OPIOIDS MARKET FOR METHADONE, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 20.OPIOIDS MARKET FOR MORPHINE, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 21.OPIOIDS MARKET FOR HYDROCODONE, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 22.OPIOIDS MARKET FOR OTHERS, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 23.OPIOIDS MARKET SEGMENTATION, BY APPLICATION
- FIGURE 24.OPIOIDS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 25.OPIOIDS MARKET FOR COUGH TREATMENT, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 26.OPIOIDS MARKET FOR DIARRHEA TREATMENT, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 27.BOEHRINGER INGELHEIM GROUP: NET SALES, 2018-2020 ($MILLION)
- FIGURE 28.BOEHRINGER INGELHEIM GROUP: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 29.BOEHRINGER INGELHEIM GROUP: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 30.ASTRAZENECA PLC: NET SALES, 2018-2020 ($MILLION)
- FIGURE 31.ASTRAZENECA PLC: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 32.ASTRAZENECA PLC: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 33.ENDO PHARMACEUTICALS, INC: NET SALES, 2018-2020 ($MILLION)
- FIGURE 34.ENDO PHARMACEUTICALS, INC: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 35.ENDO PHARMACEUTICALS, INC: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 36.JOHNSON AND JOHNSON: NET SALES, 2018-2020 ($MILLION)
- FIGURE 37.JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 38.JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 39.MALLINCKRODT PLC: NET SALES, 2018-2020 ($MILLION)
- FIGURE 40.MALLINCKRODT PLC: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 41.MALLINCKRODT PLC: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 42.PFIZER INC: NET SALES, 2018-2020 ($MILLION)
- FIGURE 43.PFIZER INC: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 44.PFIZER INC: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 45.PURDUE PHARMA L.P: NET SALES, 2018-2020 ($MILLION)
- FIGURE 46.PURDUE PHARMA L.P: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 47.PURDUE PHARMA L.P: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 48.SANOFI: NET SALES, 2018-2020 ($MILLION)
- FIGURE 49.SANOFI: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 50.SANOFI: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 51.SUN PHARMACEUTICAL INDUSTRIES LTD: NET SALES, 2018-2020 ($MILLION)
- FIGURE 52.SUN PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 53.SUN PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 54.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES, 2018-2020 ($MILLION)
- FIGURE 55.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 56.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE, BY REGION, 2020 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook